Abstract
Background: The aim of this study is to assess the difference between outcomes in clinical trials and in real-world (efficacy-effectiveness gap) of systemic treatments for ED SCLC. Methods: All patients diagnosed with ED SCLC between 2008 and 2014 in four Dutch large teaching hospitals (Santeon network) were studied. For every patient, an efficacy-effectiveness factor (EE-factor) was calculated by dividing individual patients’ overall survival (OS) by the pooled median OS assessed from clinical trials with the respective treatment. Results: From 501 diagnosed patients, 366 (73%) started first-line treatment. Table 1 outlines the real-world OS, reference OS from clinical trials, and EE-factor for the most used first-line regimens (n=358). Overall, the median EE-factor was 0.80 (p Conclusion: Overall survival of patients with ED SCLC treated with systemic therapy in real-world practice is 20% shorter than for patients included in trials. Performance status partly explained this gap.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
